EHMT2 and non-small cell lung carcinoma: Aldehyde dehydrogenase (ALDH) is widely used as a marker in CSC (75), and inhibition of EHMT2/G9a promotes transcription of ALDH2, increasing stemness in NSCLC cells and significantly enhancing resistance to paclitaxel (PTX) (76).